search
Back to results

Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors

Primary Purpose

Solid Tumors

Status
Recruiting
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
RMC-5552
Sponsored by
Revolution Medicines, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Solid Tumors focused on measuring PIK3CA, PTEN, TSC1/2, STK11, MTOR, MYC, MAPK, advanced solid tumor, advanced solid malignancies, melanoma, skin cancer, ovarian cancer, endometrium/uterus cancer, bladder cancer, cervical cancer, Carcinoma, Non-Small-Cell Lung, Neoplasms, Squamous Cell, Carcinoma, Squamous Cell, Esophageal Neoplasms, Carcinoma, Bronchogenic, Bronchial Neoplasms, Lung Neoplasms, Respiratory Tract Neoplasms, Thoracic Neoplasms, Neoplasms by Site, Neoplasms, Lung Diseases, Respiratory Tract Diseases, Neoplasms, Glandular and Epithelial, Gastrointestinal Neoplasms, Digestive System Neoplasms, Head and Neck Neoplasms, Digestive System Diseases, Esophageal Diseases, Gastrointestinal Diseases, 4EBP1

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Participants (male or female) ≥18 years of age
  • Participants who have advanced solid tumors that have failed, are intolerant to, or are considered ineligible for standard of care anticancer treatments including approved drugs for oncogenic drivers in their tumor type
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1
  • Participants in the Dose-Expansion Component must have molecular aberrations in the mTOR pathway
  • Adequate hematologic, hepatic and renal function

Exclusion Criteria:

  • Known or suspected leptomeningeal or brain metastases or spinal cord compression
  • Primary central nervous system (CNS) tumors
  • Clinically significant cardiac disease
  • Active, clinically significant interstitial lung disease or pneumonitis
  • Subjects with abnormal fasting glucose, type 1 diabetes, or uncontrolled type 2 diabetes are excluded.
  • Subjects with stomatitis or mucositis of any grade

Sites / Locations

  • UC Irvine - Chao Family Comprehensive Cancer CenterRecruiting
  • UC Davis Comprehensive Cancer CenterRecruiting
  • UC San Francisco - Helen Diller Family Comprehensive Cancer CenterRecruiting
  • Moffitt Cancer CenterRecruiting
  • Memorial Sloan Kettering Cancer CenterRecruiting
  • University of Oklahoma - Stephenson Cancer CenterRecruiting
  • Sarah Cannon Research Institute - Tennessee Oncology, PLLCRecruiting
  • Dell Seton Medical Center at University of TexasRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

RMC-5552

Arm Description

RMC-5552 for IV administration

Outcomes

Primary Outcome Measures

Number of participants with adverse events (AEs)
Incidence, nature, and severity of treatment-emergent AEs and serious AEs, including incidence and severity of findings in laboratory values or vital signs for RMC-5552 monotherapy
Number of participants with dose limiting toxicities (DLTs)
Incidence and nature of DLTs with RMC-5552 monotherapy

Secondary Outcome Measures

Cmax
Peak plasma concentration of RMC-5552
Tmax
Time to achieve peak plasma concentration of RMC-5552
Area Under the Curve (AUC)
Area under the plasma concentration time curve of RMC-5552
t1/2
Elimination half-life of RMC-5552
Accumulation Ratio
Ratio of accumulation of RMC-5552 from a single dose to steady state with repeated dosing
Overall Response Rate (ORR)
Overall response rate of RMC-5552 per RECIST v1.1
Duration of Response (DOR)
Duration of response of RMC-5552 per RECIST v1.1

Full Information

First Posted
February 25, 2021
Last Updated
March 6, 2023
Sponsor
Revolution Medicines, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT04774952
Brief Title
Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors
Official Title
A Phase 1/1b, Open-Label, Multicenter, Dose-Escalation Study of RMC 5552 Monotherapy in Adult Subjects With Relapsed/Refractory Solid Tumors
Study Type
Interventional

2. Study Status

Record Verification Date
August 2022
Overall Recruitment Status
Recruiting
Study Start Date
April 7, 2021 (Actual)
Primary Completion Date
March 31, 2024 (Anticipated)
Study Completion Date
March 31, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Revolution Medicines, Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) profiles of escalating doses of RMC-5552 monotherapy in adult participants with relapsed/refractory solid tumors and to identify the recommended Phase 2 dose (RP2D).
Detailed Description
This is an open-label, multicenter, Phase 1/1b study of RMC-5552 monotherapy in participants with advanced relapsed or refractory solid tumors. The study will include 2 components: 1) a Dose-Escalation Component for participants with relapsed or refractory solid tumors and 2) a Dose-Expansion Component for participants with relapsed or refractory solid tumors harboring certain specific mutations/rearrangements that result in hyperactivation of the mTOR pathway. Participants will be treated until disease progression per RECIST v1.1, unacceptable toxicity, or other criteria for withdrawal are met, whichever occurs first.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Solid Tumors
Keywords
PIK3CA, PTEN, TSC1/2, STK11, MTOR, MYC, MAPK, advanced solid tumor, advanced solid malignancies, melanoma, skin cancer, ovarian cancer, endometrium/uterus cancer, bladder cancer, cervical cancer, Carcinoma, Non-Small-Cell Lung, Neoplasms, Squamous Cell, Carcinoma, Squamous Cell, Esophageal Neoplasms, Carcinoma, Bronchogenic, Bronchial Neoplasms, Lung Neoplasms, Respiratory Tract Neoplasms, Thoracic Neoplasms, Neoplasms by Site, Neoplasms, Lung Diseases, Respiratory Tract Diseases, Neoplasms, Glandular and Epithelial, Gastrointestinal Neoplasms, Digestive System Neoplasms, Head and Neck Neoplasms, Digestive System Diseases, Esophageal Diseases, Gastrointestinal Diseases, 4EBP1

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
108 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
RMC-5552
Arm Type
Experimental
Arm Description
RMC-5552 for IV administration
Intervention Type
Drug
Intervention Name(s)
RMC-5552
Intervention Description
RMC-5552 for IV administration
Primary Outcome Measure Information:
Title
Number of participants with adverse events (AEs)
Description
Incidence, nature, and severity of treatment-emergent AEs and serious AEs, including incidence and severity of findings in laboratory values or vital signs for RMC-5552 monotherapy
Time Frame
up to 3 years
Title
Number of participants with dose limiting toxicities (DLTs)
Description
Incidence and nature of DLTs with RMC-5552 monotherapy
Time Frame
21 days
Secondary Outcome Measure Information:
Title
Cmax
Description
Peak plasma concentration of RMC-5552
Time Frame
up to 3 years
Title
Tmax
Description
Time to achieve peak plasma concentration of RMC-5552
Time Frame
up to 3 years
Title
Area Under the Curve (AUC)
Description
Area under the plasma concentration time curve of RMC-5552
Time Frame
up to 3 years
Title
t1/2
Description
Elimination half-life of RMC-5552
Time Frame
up to 3 years
Title
Accumulation Ratio
Description
Ratio of accumulation of RMC-5552 from a single dose to steady state with repeated dosing
Time Frame
up to 3 years
Title
Overall Response Rate (ORR)
Description
Overall response rate of RMC-5552 per RECIST v1.1
Time Frame
up to 3 years
Title
Duration of Response (DOR)
Description
Duration of response of RMC-5552 per RECIST v1.1
Time Frame
up to 3 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Participants (male or female) ≥18 years of age Participants who have advanced solid tumors that have failed, are intolerant to, or are considered ineligible for standard of care anticancer treatments including approved drugs for oncogenic drivers in their tumor type Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 Participants in the Dose-Expansion Component must have molecular aberrations in the mTOR pathway Adequate hematologic, hepatic and renal function Exclusion Criteria: Known or suspected leptomeningeal or brain metastases or spinal cord compression Primary central nervous system (CNS) tumors Clinically significant cardiac disease Active, clinically significant interstitial lung disease or pneumonitis Subjects with abnormal fasting glucose, type 1 diabetes, or uncontrolled type 2 diabetes are excluded. Subjects with stomatitis or mucositis of any grade
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Revolution Medicines, Inc.
Phone
(650) 779-2300
Email
CT-Inquiries@RevMed.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Revolution Medicines, Inc
Organizational Affiliation
Revolution Medicines, Inc.
Official's Role
Study Director
Facility Information:
Facility Name
UC Irvine - Chao Family Comprehensive Cancer Center
City
Irvine
State/Province
California
ZIP/Postal Code
92868
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Oliver Quines, MD
Phone
714-456-6244
Email
ucstudy@uci.edu
First Name & Middle Initial & Last Name & Degree
Sai-Hong Ignatius Ou, MD
Facility Name
UC Davis Comprehensive Cancer Center
City
Sacramento
State/Province
California
ZIP/Postal Code
95817
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Diem Le
Phone
916-734-4942
Email
msle@ucdavis.edu
First Name & Middle Initial & Last Name & Degree
Jonathan Riess, MD
Facility Name
UC San Francisco - Helen Diller Family Comprehensive Cancer Center
City
San Francisco
State/Province
California
ZIP/Postal Code
94115
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Christian Kelly
Phone
415-353-4084
Email
christian.kelly@ucsf.edu
First Name & Middle Initial & Last Name & Degree
Phu Lam
Email
phu.lam@ucsf.edu
First Name & Middle Initial & Last Name & Degree
Pamela Munster, MD
Facility Name
Moffitt Cancer Center
City
Tampa
State/Province
Florida
ZIP/Postal Code
33612
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Samuel Gobran
Phone
813-745-4610
Email
Phase1patientreferral@moffitt.org
First Name & Middle Initial & Last Name & Degree
Eric Haura, MD
Facility Name
Memorial Sloan Kettering Cancer Center
City
New York
State/Province
New York
ZIP/Postal Code
10021
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Carly Luk
Email
lukc@mskcc.org
First Name & Middle Initial & Last Name & Degree
Alison Schram, MD
Facility Name
University of Oklahoma - Stephenson Cancer Center
City
Oklahoma City
State/Province
Oklahoma
ZIP/Postal Code
73104
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Email
Phase1-Referrals@ouhsc.edu
First Name & Middle Initial & Last Name & Degree
Abdul Naqash, MD
Facility Name
Sarah Cannon Research Institute - Tennessee Oncology, PLLC
City
Nashville
State/Province
Tennessee
ZIP/Postal Code
37203
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
615-339-4214
Email
asksarah@sarahcannon.com
First Name & Middle Initial & Last Name & Degree
Howard Burris, MD
Facility Name
Dell Seton Medical Center at University of Texas
City
Austin
State/Province
Texas
ZIP/Postal Code
78712
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Monae Carpenter
Phone
512-495-5420
Email
monae.carpenter@austin.utexas.edu
First Name & Middle Initial & Last Name & Degree
Anna Capasso, MD

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors

We'll reach out to this number within 24 hrs